

World Journal of *Gastrointestinal Endoscopy*

World J Gastrointest Endosc 2017 October 16; 9(10): 499-539



MINIREVIEWS

- 499 Endoscopic ultrasound: Current roles and future directions
Friedberg SR, Lachter J
- 506 Endoscopic ultrasound elastography for solid pancreatic lesions
Chantarojanasiri T, Kongkam P

ORIGINAL ARTICLE

Retrospective Study

- 514 Oral esomeprazole vs injectable omeprazole for the prevention of hemorrhage after endoscopic submucosal dissection
Uchiyama T, Higurashi T, Kuriyama H, Kondo Y, Hata Y, Nakajima A

CASE REPORT

- 521 Two case reports of acute upper gastrointestinal bleeding from duodenal ulcers after Roux-en-Y gastric bypass surgery: Endoscopic diagnosis and therapy by single balloon or push enteroscopy after missed diagnosis by standard esophagogastroduodenoscopy
Hakim S, Reddy SRR, Batke M, Polidori G, Cappell MS
- 529 Cap polyposis refractory to *Helicobacter pylori* eradication treated with endoscopic submucosal dissection
Murata M, Sugimoto M, Ban H, Otsuka T, Nakata T, Fukuda M, Inatomi O, Bamba S, Kushima R, Andoh A
- 535 Endoscopic ultrasound-guided pancreaticogastrostomy for symptomatic pancreatic duct obstruction caused by migrated pancreatic stent
Lu L, Jin HB, Yang JF, Zhang XF

Contents

World Journal of Gastrointestinal Endoscopy
Volume 9 Number 10 October 16, 2017

ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Endoscopy*, Dr. Stepan Suchanek, MD, PhD, Chief Doctor, Department of Internal Medicine, 1st Faculty of Medicine of the Charles University, Prague CZ16902, Czech Republic

AIM AND SCOPE

World Journal of Gastrointestinal Endoscopy (*World J Gastrointest Endosc*, *WJGE*, online ISSN 1948-5190, DOI: 10.4253) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJGE covers topics concerning gastroscopy, intestinal endoscopy, colonoscopy, capsule endoscopy, laparoscopy, interventional diagnosis and therapy, as well as advances in technology. Emphasis is placed on the clinical practice of treating gastrointestinal diseases with or under endoscopy.

We encourage authors to submit their manuscripts to *WJGE*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

INDEXING/ABSTRACTING

World Journal of Gastrointestinal Endoscopy is now indexed in Emerging Sources Citation Index (Web of Science), PubMed, and PubMed Central.

FLYLEAF

I-III Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Ya-Jing Lu*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Fang-Fang Ji*
Proofing Editorial Office Director: *Xiu-Xia Song*

NAME OF JOURNAL
World Journal of Gastrointestinal Endoscopy

ISSN
ISSN 1948-5190 (online)

LAUNCH DATE
October 15, 2009

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Atsushi Imagawa, PhD, Director, Doctor, Department of Gastroenterology, Mitoyo General Hospital, Kan-onji, Kagawa 769-1695, Japan
Juan Manuel Herrerias Gutierrez, PhD, Academic Fellow, Chief Doctor, Professor, Unidad de Gestión Clínica de Aparato Digestivo, Hospital Universitario Virgen Macarena, Sevilla 41009, Spain

EDITORIAL BOARD MEMBERS
All editorial board members resources online at <http://www.wjnet.com>

www.wjnet.com/1948-5190/editorialboard.htm

EDITORIAL OFFICE
Xiu-Xia Song, Director
World Journal of Gastrointestinal Endoscopy
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjnet.com
Help Desk: <http://www.fjgpublishing.com/helpdesk>
<http://www.wjnet.com>

PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjnet.com
Help Desk: <http://www.fjgpublishing.com/helpdesk>
<http://www.wjnet.com>

PUBLICATION DATE
October 16, 2017

COPYRIGHT
© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
<http://www.wjnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.fjgpublishing.com>

Cap polyposis refractory to *Helicobacter pylori* eradication treated with endoscopic submucosal dissection

Masaki Murata, Mitsushige Sugimoto, Hiromitsu Ban, Taketo Otsuka, Toshiro Nakata, Masahide Fukuda, Osamu Inatomi, Shigeki Bamba, Ryoji Kushima, Akira Andoh

Masaki Murata, Taketo Otsuka, Toshiro Nakata, Osamu Inatomi, Shigeki Bamba, Akira Andoh, Department of Gastroenterology, Shiga University of Medical Science Hospital, Otsu 520-2192, Japan

Mitsushige Sugimoto, Hiromitsu Ban, Division of Digestive Endoscopy, Shiga University of Medical Science Hospital, Otsu 520-2192, Japan

Masahide Fukuda, Ryoji Kushima, Department of Clinical Laboratory Medicine, Shiga University of Medical Science Hospital, Otsu 520-2192, Japan

Author contributions: Murata M, Sugimoto M, Ban H, Otsuka T, Nakata T, Fukuda M, Inatomi O, Bamba S, Kushima R and Andoh A collected and analyzed the patient's clinical data and wrote the paper.

Institutional review board statement: Approval of this case report was not given in advance by the Institutional Review Board of Shiga University of Medical Science.

Informed consent statement: A patient of this case provided informed written consent prior to the endoscopic procedure and treatment.

Conflict-of-interest statement: No conflict of interest to declare.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Correspondence to: Mitsushige Sugimoto, MD, PhD, Division of Digestive Endoscopy, Shiga University of Medical Science Hospital, Seta Tsukinowa-cho, Otsu, Shiga 520-2192,

Japan. sugimo@belle.shiga-med.ac.jp
Telephone: +81-77-5482618
Fax: +81-77-5482618

Received: April 6, 2017

Peer-review started: April 10, 2017

First decision: May 16, 2017

Revised: May 24, 2017

Accepted: June 30, 2017

Article in press: July 3, 2017

Published online: October 16, 2017

Abstract

Cap polyposis is a rare intestinal disorder. Characteristic endoscopic findings are multiple inflammatory polypoid lesions covered by caps of fibrous purulent exudate. Although a specific treatment has not been established, some studies have suggested that eradication therapy for *Helicobacter pylori* (*H. pylori*) is effective. We report a case of a 20-year-old man with cap polyposis presenting with hematochezia. Colonoscopy showed the erythematous polyps with white caps from the sigmoid colon to rectum. Histopathological findings revealed elongated, tortuous, branched crypts lined by hyperplastic epithelium with a mild degree of fibromusculosis in the lamina propria. Although *H. pylori* eradication was instituted, there was no improvement over six months. We then performed *en bloc* excision of the polyps by endoscopic submucosal dissection (ESD), which resulted in complete resolution of symptoms. ESD may be a treatment option for cap polyposis refractory to conservative treatments. We review the literature concerning treatment for cap polyposis and clinical outcomes.

Key words: Endoscopic submucosal dissection; Cap polyposis; Eradication therapy; *Helicobacter pylori*

© The Author(s) 2017. Published by Baishideng Publishing

Group Inc. All rights reserved.

Core tip: Although for cap polyposis, conservative treatment should be selected as first-line therapy, the optimal treatment of cap polyposis refractory to conservative treatment has not been established. Endoscopic submucosal dissection may be a treatment option for cases refractory to conservative treatment.

Murata M, Sugimoto M, Ban H, Otsuka T, Nakata T, Fukuda M, Inatomi O, Bamba S, Kushima R, Andoh A. Cap polyposis refractory to *Helicobacter pylori* eradication treated with endoscopic submucosal dissection. *World J Gastrointest Endosc* 2017; 9(10): 529-534 Available from: URL: <http://www.wjgnet.com/1948-5190/full/v9/i10/529.htm> DOI: <http://dx.doi.org/10.4253/wjge.v9.i10.529>

INTRODUCTION

Cap polyposis is a rare intestinal disorder with unique clinical, endoscopic, and histological findings. Clinical symptoms include mucoid and bloody diarrhea, abdominal pain, tenesmus, weight loss, and dysplasia. Endoscopy typically reveals multiple reddish, mucus-capped inflammatory polyps in the rectosigmoid area with normal mucosa interspersed between the polyps^[1]. Pathologically, the surfaces of these inflammatory polyps are covered by a thick layer of fibrinopurulent exudate, hence the term “cap”^[1]. However, the etiology of cap polyposis is unclear and its clinical course varies from spontaneous clinical and endoscopic remission without treatment^[2-4] to persistent disease refractory to conservative treatment^[5-7], requiring surgical resection. Little is known about its long-term course.

The optimal treatment for cap polyposis has not been established^[2-16]. Some cases have been treated successfully by the avoidance of straining at defecation^[8], antimicrobial agents (*i.e.*, metronidazole)^[9], steroids^[2], immunomodulators (*i.e.*, infliximab)^[12], endoscopic therapy^[13,14] and surgical resection^[5-7]. Recently, the efficacy of *Helicobacter pylori* (*H. pylori*) eradication therapy for *H. pylori*-positive patients with cap polyposis has been reported^[10,11,15,16], and in 2016 the Japanese Society for *Helicobacter* Research added cap polyposis as a possible *H. pylori*-associated disease in its treatment guidelines. However, no treatments for *H. pylori*-negative cap polyposis or *H. pylori*-positive cases refractory to eradication therapy have yet been established.

Here, we report a case of *H. pylori*-negative cap polyposis refractory to *H. pylori* eradication therapy that was successfully treated with endoscopic submucosal dissection (ESD). We also review the literature concerning conservative and endoscopic treatments for cap polyposis.

CASE REPORT

A 20-year-old Japanese man presented with a 1-year history of hematochezia and tenesmus. He denied

straining at stool and had no history of anal prolapse. His past medical and family history were unremarkable. Laboratory tests revealed mild hypoproteinemia (serum albumin 3.9 g/L), but no hepatic or renal dysfunction, leukocytosis, elevation of C-reactive protein, or anemia. Colonoscopy revealed the characteristic appearance of cap polyposis, with approximately 20-30 erythematous variform inflammatory polyps with white caps of fibrinopurulent exudate from the sigmoid colon to the rectum (Figure 1A and B). Magnification endoscopy with narrow-band imaging showed amorphous exudate in the white caps overlying long branching tortuous crypts in the basal part of the polyps (Figure 1C and D). Endoscopic ultrasonography (EUS) with radial array scanning showed significant thickening of the mucosa without evidence of invasion into the submucosa (Figure 1E). Histologic findings from a polyp revealed elongated, tortuous, branched crypts lined with hyperplastic epithelium with inflammatory cell infiltration and a mild degree of fibromusculosis in the lamina propria (Figure 2). The surface of the polyps was covered by thick inflammatory granulation tissue with exudate (Figure 2). The intervening mucosa between lesions was histologically normal. Computed tomography and magnetic resonance imaging showed multiple elevated lesions thickening the walls of the sigmoid colon and rectum (Figure 3A and B). Barium enema showed multiple raised mucosal lesions without stenosis or sclerotic changes in the sigmoid colon and rectum (Figure 3C). The differential diagnosis included the mucosal prolapse syndrome, inflammatory polyps, colon cancer, malignant lymphoma, inflammatory bowel disease, and adenomatous polyposis. We diagnosed cap polyposis based on the endoscopic and histopathological characteristics.

The patient had no evidence of *H. pylori* infection by urea breath test, anti-*H. pylori* antibody, or endoscopic findings (*i.e.*, gastric mucosal atrophy or diffuse redness of gastric mucosa). However, according to previous evidence that *H. pylori* eradication therapy was effective for patients with cap polyposis^[10,11,15,16], *H. pylori* eradication therapy with vonoprazan 20 mg, amoxicillin 750 mg and clarithromycin 200 mg twice daily for 7 d was initiated. Abdominal symptoms (*i.e.*, hematochezia and tenesmus), bowel habits, and endoscopic findings did not improve over the six months after therapy. Therefore, as conservative alternative treatment, we performed *en bloc* excision of the polyps with ESD (Figure 4). After resection, the patient's symptoms disappeared and he had no endoscopic evidence of recurrence for six months.

DISCUSSION

We report a case of a patient with cap polyposis refractory to *H. pylori* eradication therapy who then underwent *en bloc* excision of polyps by ESD with good results. This is the first report of the efficacy of ESD for treatment of cap polyposis. More studies of ESD as a treatment option for cap polyposis are needed to validate




Figure 1 Endoscopic findings of multiple inflammatory polyps. A and B: Caps of fibrinopurulent exudate from the sigmoid colon to the rectum interspersed with normal colonic mucosa; C and D: Magnifying endoscopy shows an area in the cap of amorphous fibrinopurulent exudate and tortuous and long branching crypts under the cap; E: Endoscopic ultrasonography showed significant thickening of the colonic mucosa layers.




Figure 2 Microscopic findings of inflammatory polyps show elongated, tortuous, branched, and dilated crypts with epithelial hyperplasia, inflammatory granulation tissue and a mild degree of fibromusculosis in the lamina propria. Hematoxylin-Eosin stain, $\times 4$ (A) and $\times 20$ (B).

its use instead of surgical resection.

Diagnosis of cap polyposis

Cap polyposis can be difficult to diagnose. It can resemble mucosal prolapse syndrome (MPS). There has been a debate about whether cap polyposis is a specific form of inflammatory disorder or part of a spectrum of MPS^[12]. MPS and cap polyposis share some clinical, endoscopic, and histological features. Both diseases show infiltration of inflammatory cells with elongated stroma and fibromuscular obliteration of the lamina propria. However, the fibromuscular obliteration is more marked in cap polyposis. MPS is usually confined to the

rectum, but cap polyposis usually involves the sigmoid and/or descending colon as well as the rectum. EUS findings in cap polyposis show significant thickening of the mucosa^[9], whereas MPS is characterized by smooth, diffuse thickening of the submucosa and minimal thickening of the lamina propria^[17].

Cap polyposis and protein loss

Common clinical features of cap polyposis are hematochezia (82%), chronic straining (64%), and mucous diarrhea (46%)^[1]. When mucous diarrhea is severe and/or continuous for long periods, excessive protein loss is observed as a result^[1,5]. Direct loss of protein was




Figure 3 Multiple elevated lesions with wall thickening in the sigmoid colon. Rectum on computed tomography (A) and magnetic resonance imaging (B); Barium enema shows a collection of small sessile polyps in the sigmoid colon and rectum (C).




Figure 4 Endoscopic submucosal dissection. Post-dissection ulcers after endoscopic submucosal dissection at the sigmoid colon and rectum (A). Fresh specimen of cap polyposis after endoscopic submucosal dissection (B) and fixed specimen (C). The fixed specimen revealed bleeding into the polyps. Microscopic findings of inflammatory polyps [HE stain, $\times 4$ (D)].

demonstrated in a case of cap polyposis by scintigraphy with technetium 99m-labeled diethylenetriaminepentaacetic acid complexed to human serum albumin^[18]. In our case, blood tests revealed mild hypoproteinemia, with an albumin level 39 g/L, possibly secondary to protein loss from mucous diarrhea.

Cap polyposis and *H. pylori* infection

Cap polyposis has been attributed to colonic dysmotility, immune abnormalities, bacterial infection (*i.e.*, *H. pylori*) or other unknown pathogens. Géhénot *et al.*^[19] suggested the possibility of bacterial infection, reporting on a cap polyposis patient who had no evidence of

colonic dysmotility and who was successfully treated with metronidazole. Of the myriad gut microbiota, although *H. pylori* is not detected in mucosa obtained from cap polyposis lesions^[10], most cases of cap polyposis with *H. pylori* infection have resolved after *H. pylori* eradication therapy^[10,11,15,16,18]. *H. pylori* infection is well-known to cause not only gastroduodenal diseases, but also diseases such as idiopathic thrombocytopenic purpura and chronic idiopathic urticaria^[20,21]. In addition, eradication therapy often induces regression of mucosa-associated lymphoid tissue (MALT) lymphoma in the rectum and thyroid^[22]. Although an *H. pylori*-associated immune reaction may play a role in the development of some cases of cap

polyposis, there is no evidence for efficacy of *H. pylori* eradication therapy in *H. pylori*-negative cap polyposis patients, as in our case. Because the development of cap polyposis with active inflammation in the colonic mucosa may be related to other bacterial infections that are also sensitive to the antimicrobial agents used in *H. pylori* eradication therapy (*i.e.*, clarithromycin, amoxicillin, and metronidazole), we selected eradication therapy as the first-line treatment. Although eradication failed to cure the cap polyposis, further studies will be required to investigate whether other pathogens are related to this diagnosis, and whether their eradication can effect resolution.

Cap polyposis and endoscopic treatment

The efficacy of endoscopic treatment, such as polypectomy and endoscopic mucosal resection (EMR), for cap polyposis has been reported^[12,14]. However, *en bloc* excision is difficult to perform with conventional EMR, and the use of surgical resection is more frequent^[5-7]. Although there have been no reports of malignant transformation, surgical resection may be excessive for the treatment of cap polyposis. We consider ESD *en bloc* excision to be less invasive, and also can prevent recurrence.

ESD, an endoscopic procedure that originated in Japan and Korea in the late 1990s which has since spread rapidly to other nations, is now commonly used to treat gastrointestinal tumors^[23,24]. ESD allows complete pathological assessment, proving this technique superior to polypectomy or conventional EMR to prevent recurrence^[25]. To date, no case of cap polyposis treated with ESD has been reported. Our present case suggests that ESD may be an effective treatment for intractable cap polyposis, with lower invasiveness than surgical resection. Our patient remains under surveillance for recurrence.

Conclusion

For cap polyposis, conservative treatment should be selected as first-line therapy. In particular, we recommend eradication therapy for *H. pylori* infection. To our knowledge, however, the optimal treatment of cap polyposis refractory to conservative medical treatment has not been established. This is the first report of cap polyposis refractory to conservative medical treatment effectively treated with ESD. We believe that ESD is less invasive and more effective than surgical resection in cases refractory to conservative treatment. ESD may be a treatment option for cap polyposis cases refractory to conservative medical treatments, such as *H. pylori* eradication, metronidazole, steroids, and infliximab. Further investigation is required.

COMMENTS

Case characteristics

A 20-year-old Japanese man with cap polyposis located in sigmoid colon and rectum refractory to *Helicobacter pylori* (*H. pylori*) eradication and resected with

endoscopic submucosal dissection.

Clinical diagnosis

Cap polyposis.

Differential diagnosis

Although the differential diagnosis includes the mucosal prolapse syndrome (MPS), inflammatory polyps, colon cancer, malignant lymphoma, inflammatory bowel disease, and adenomatous polyposis, MPS is most possible disease as differentiation disease, because cap polyposis and MPS share some clinical, endoscopic, and histological features.

Laboratory diagnosis

Although mild hypoproteinemia was revealed, there was no hepatic or renal dysfunction, leukocytosis, elevation of C-reactive protein, or anemia.

Imaging diagnosis

Colonoscopy revealed the characteristic appearance of cap polyposis, with approximately 20-30 erythematous variform inflammatory polyps with white caps of fibrinopurulent exudate from the sigmoid colon to the rectum.

Pathological diagnosis

Pathological findings revealed elongated, tortuous, branched crypts lined with hyperplastic epithelium with inflammatory cell infiltration and a mild degree of fibromusculosis in the lamina propria in the polypoid lesion and thick inflammatory granulation tissue in the surface of the polyps.

Treatment

Because this case was refractory to *H. pylori* eradication as the first-line therapy, *en bloc* excision of polyposis with endoscopic submucosal dissection (ESD) was selected as second-line therapy.

Related reports

Previously, although endoscopic treatment including polypectomy and EMR, and conservative medical treatments including *H. pylori* eradication, metronidazole, steroids, and infliximab, had been reported, the optimal treatment for cap polyposis has not been established.

Experiences and lessons

ESD may be a treatment option for cap polyposis cases refractory to conservative treatments (*i.e.*, *H. pylori* eradication, metronidazole, steroids, and infliximab).

Peer-review

The paper is well written.

REFERENCES

- 1 Ng KH, Mathur P, Kumarasinghe MP, Eu KW, Seow-Choen F. Cap polyposis: further experience and review. *Dis Colon Rectum* 2004; **47**: 1208-1215 [PMID: 15164251 DOI: 10.1007/s10350-004-0561-8]
- 2 Chang HS, Yang SK, Kim MJ, Ye BD, Byeon JS, Myung SJ, Kim JH. Long-term outcome of cap polyposis, with special reference to the effects of steroid therapy. *Gastrointest Endosc* 2012; **75**: 211-216 [PMID: 22078102 DOI: 10.1016/j.gie.2011.08.027]
- 3 Sasaki Y, Takeda H, Fujishima S, Sato T, Nishise S, Abe Y, Ajioka Y, Kawata S, Ueno Y. Nine-year follow-up from onset to spontaneous complete remission of cap polyposis. *Intern Med* 2013; **52**: 351-354 [PMID: 23370743]
- 4 Ohkawara T, Kato M, Nakagawa S, Nakamura M, Takei M, Komatsu Y, Shimizu Y, Takeda H, Sugiyama T, Asaka M. Spontaneous resolution of cap polyposis: case report. *Gastrointest Endosc* 2003; **57**: 599-602 [PMID: 12665781 DOI: 10.1067/mge.2003.166]
- 5 Gallegos M, Lau C, Bradley DP, Blanco L, Keshavarzian A, Jakate SM. Cap polyposis with protein-losing enteropathy. *Gastroenterol Hepatol* (N Y) 2011; **7**: 415-420 [PMID: 21869875]

- Gastrointest Liver Dis* 2014; **23**: 203-206 [PMID: 24949613]
- 17 **Hizawa K**, Iida M, Suekane H, Mibu R, Mochizuki Y, Yao T, Fujishima M. Mucosal prolapse syndrome: diagnosis with endoscopic US. *Radiology* 1994; **191**: 527-530 [PMID: 8153334 DOI: 10.1148/radiology.191.2.8153334]
- 18 **Nakagawa Y**, Nagai T, Okawara H, Nakashima H, Tasaki T, Soma W, Hisamatsu A, Watada M, Murakami K, Fujioka T. Cap polyposis (CP) which relapsed after remission by avoiding straining at defecation and was cured by *Helicobacter pylori* eradication therapy. *Intern Med* 2009; **48**: 2009-2013 [PMID: 19952483]
- 19 **Géhénot M**, Colombel JF, Wolschies E, Quandalle P, Gower P, Lecomte-Houcke M, Van Kruiningen H, Cortot A. Cap polyposis occurring in the postoperative course of pelvic surgery. *Gut* 1994; **35**: 1670-1672 [PMID: 7828996]
- 20 **Take S**, Mizuno M, Ishiki K, Hamada F, Yoshida T, Yokota K, Okada H, Yamamoto K. Seventeen-year effects of eradicating *Helicobacter pylori* on the prevention of gastric cancer in patients with peptic ulcer; a prospective cohort study. *J Gastroenterol* 2015; **50**: 638-644 [PMID: 25351555 DOI: 10.1007/s00535-014-1004-5]
- 21 **Malfertheiner P**, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM. Management of *Helicobacter pylori* infection-the Maastricht V/Florence Consensus Report. *Gut* 2017; **66**: 6-30 [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288]
- 22 **Kalpadakis C**, Pangalis GA, Vassilakopoulos TP, Kyriakaki S, Yiakoumis X, Sachanas S, Moschogiannis M, Tsirkinidis P, Korkolopoulou P, Papadaki HA, Angelopoulou MK. Clinical aspects of malt lymphomas. *Curr Hematol Malig Rep* 2014; **9**: 262-272 [PMID: 25240474 DOI: 10.1007/s11899-014-0218-1]
- 23 **Fujishiro M**. Endoscopic submucosal dissection for stomach neoplasms. *World J Gastroenterol* 2006; **12**: 5108-5112 [PMID: 16937520 DOI: 10.3748/wjg.v12.i32.5108]
- 24 **Ninomiya Y**, Oka S, Tanaka S, Nishiyama S, Tamaru Y, Asayama N, Shigita K, Hayashi N, Chayama K. Risk of bleeding after endoscopic submucosal dissection for colorectal tumors in patients with continued use of low-dose aspirin. *J Gastroenterol* 2015; **50**: 1041-1046 [PMID: 25682173 DOI: 10.1007/s00535-015-1053-4]
- 25 **Hull MJ**, Mino-Kenudson M, Nishioka NS, Ban S, Sepehr A, Puricelli W, Nakatsuka L, Ota S, Shimizu M, Brugge WR, Lauwers GY. Endoscopic mucosal resection: an improved diagnostic procedure for early gastroesophageal epithelial neoplasms. *Am J Surg Pathol* 2006; **30**: 114-118 [PMID: 16330950]

P-Reviewer: Zamani M **S-Editor:** Qi Y **L-Editor:** A
E-Editor: Lu YJ





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

